# A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002

> **NCT07726212** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Hangzhou MacroLink Biopharmaceutical LLC** · enrollment: 143 (estimated)

## Conditions studied

- Advanced Esophageal Cancer
- Advanced Lung Cancer

## Interventions

- **DRUG:** MC002（ADC）

## Key facts

- **NCT ID:** NCT07726212
- **Lead sponsor:** Hangzhou MacroLink Biopharmaceutical LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 143 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07726212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07726212, "A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07726212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*